大川 伸一 先生のプロフィール

大川 伸一 先生

おおかわ しんいち

大川 伸一 先生

地方独立行政法人神奈川県立病院機構神奈川県立がんセンター 病院長

専門分野

肝胆膵悪性腫瘍の診断と治療

紹介

医学部卒業後、消化器内科医として主に肝胆膵治療の専門医として研鑽を積み続けてきた。現在所属する神奈川県立がんセンターでは、がんに対する治療を続ける医師としての立場と、神奈川県内のがん診療向上のための各種取組の指揮を執る病院長としての立場を兼ねている。

略歴

1987年 横浜市立大学医学部付属病院第3内科 常勤特別職
1987年 藤沢市民病院 消化器内科
1989年 神奈川県立がんセンター 内科2科(肝胆膵内科)医師
1992年 同 医長
2002年 同 部長
2013年 同 副院長
2016年 同 病院長

所属学会・資格・役職など

【所属学会】
日本内科学会 認定内科医・指導医
日本消化器病学会 消化器病専門医・指導医
日本癌治療学会
日本臨床腫瘍学会
日本癌学会
日本肝臓学会 肝臓専門医
日本消化器内視鏡学会
日本膵臓学会
日本胆道学会
American Society of Clinical Oncology (ASCO) Active member
European Society of Medical Oncology (ESMO) Member
【研究活動】
厚生労働科学研究委託費「切除不能膵癌に対する標準治療の確立に関する研究」班班員
厚生労働省がん研究開発費「進行肝胆膵がんの治療法の開発に関する研究」班班員

受賞・著書・論文など

【受賞】
第52回日本癌治療学会(2014年) 優秀演題賞

【論文】
1) Hideki Ueno, Takuji Okusaka, Akihiro Funakoshi, Hiroshi Ishii, Kenji Yamao, Osamu Ishikawa, Shinichi Ohkawa, Soh Saito. A Phase Ⅱ study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2007 59; 447-454.
2) Soichiro Morinaga, Kazuo Tarao, Yuji Yamamoto, Yoshiyasu Nakamura, Yasushi Rino, Kaoru Miyakawa, Shinichi Ohkawa, Makoto Akaike, Yukio Sugimasa, Shoji Takemiya. Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-re

【受賞】
第52回日本癌治療学会(2014年) 優秀演題賞

【論文】
1) Hideki Ueno, Takuji Okusaka, Akihiro Funakoshi, Hiroshi Ishii, Kenji Yamao, Osamu Ishikawa, Shinichi Ohkawa, Soh Saito. A Phase Ⅱ study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2007 59; 447-454.
2) Soichiro Morinaga, Kazuo Tarao, Yuji Yamamoto, Yoshiyasu Nakamura, Yasushi Rino, Kaoru Miyakawa, Shinichi Ohkawa, Makoto Akaike, Yukio Sugimasa, Shoji Takemiya. Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative for hepatocellular carcinoma. J Gastroen Hepatol. 2007 22: 1249-1255.
3) Naohiro Yonemoto, Junji Furuse, Takuji Okusaka, Kenji Yamao, Akihiro Funakoshi, Shinichi Ohkawa, Narikazu Boku, Katsuaki Tanaka, Michitaka Nagase, Hiromitsu Saisho and Toshiya Sato. A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer. Jpn J Clin Oncol. 2007 37(11):843-851.
4) Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008 Apr;61(4):615-21.
5) Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55.
6) Niwa T, Ueno M, Ohkawa S, Yoshida T, Doiuchi T, Ito K, Inoue T. Advanced pancreatic cancer; the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol. 2009 82:28-34.
7) Miyakawa K, Tarao K, Ohshige K, Morinaga S, Ohkawa S, Okamoto N, Shibuya A, Adachi S, Miura Y, Fujiyama S, Miyase S, Tomita K. High serum alanine amminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis. Scand J Gastroentero. 2009 44:1340-1348.
8) Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T. A phase Ⅱstudy of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol. 2009 65:113-120.
9) Ueno M, Niwa T, Ohkawa S, Amano A, Masaki T, Miyakawa K, Yoshida T. The usefullness of perfusion-weighted magnetic resonance imaging in advanced pancreatic cancer. Pancreas. 2009 38:644-648.
10) Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010 Aug;103(4):469-74.
11) Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H; JCOG Gastrointestinal Oncology Study Group. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 2010 Jun: 40(6):573-9.
12) Okusaka T, Furuse J, Funakoshi A, Ioka T, Yamao K, Ohkawa S, Boku N, Komatsu Y, Nakamori S, Iguchi H, Ito T, Nakagawa K, Nakachi K. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci. 2011 Feb;102(2):425-31.
13) Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 March,12(3). 256-262.
14) Morimoto M, Numata K. Kondo M, Hidaka H, Takada J, Shibuya A, Kobayashi S, Ohkawa S, Okuse C, Morita S, Taguri M, Tanaka K. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011 41(4):296-302
15) Hideki Ueno, Takuji Okusaka, Juniji Furuse, Keniji Yamao, Akihiro Funakoshi, Narikazu Boku, Shinichi Ohkawa, Osamu Yokosuka, Katsuaki Tanaka, Fuminori Moriyasu, Shoji Nakamori and Toshiya Sato. Multienter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer. Jpn J Clin Oncol. 2011 41(8) 953-958.
16) Soichiro M, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi,Y. Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1(hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemciabine Monotherapy. Ann Surg Oncol. 2012 19:s558-s564.
17) Kazuo Tarao, Kaoru Miyakawa, Yohei Miyagi, Shinichi Ohkawa, Soichiro Morinaga, Kenji Oshige, Naoto Yamamoto, Makoto Ueno, Satoshi Kobayashi, Ryou Kameda, Setsuo Tamai, Yoshiyasu Nakamura, Yuichi Endo, Yoichi Kameda and Masahiko Okudaira. Severe Inflammation in the Background Liver Cirrhosis Correlates with the Development of Poorly Differentiated HCC in HCV-Associated Liver Cirrhosis. Internal Medicine. 2012 .51, 2495-2501.
18) Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, Morinaga S. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol. 2012 Sep;42(9):800-6.
19) Watanabe T, Morinaga S, Akaike M, Numata M, Tamagawa H, Yamamoto N, Shiozawa M, Ohkawa S, Kameda Y, Nakamura Y, Miyagi Y. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery. Eur J Surg Oncol. 2012 Nov;38(11):1051-7.
20) Morizane C,Okusaka T, ueno H, kondo S, Ikeda M, Furuse J, Ohkawa S, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Cancer Chemother Pharmacol. 2012 69(4):957-64.
21) Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. J Clin Oncol. 2013 31(13):1640-8.
22) Kazuo Tarao, Shinichi Ohkawa, Yohei Miyagi,Soichiro Morinaga,Kenji Ohshige,Naoto Yamamoto, Makoto Ueno, Satoshi Kobayashi, Ryo Kameda, Setsuo Tamai, Yoshiyasu Nakamura, Kaoru Miyakawa, Yoichi Kameda, Masahiko Okudaira. Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated licer cirrhosis. Scand J Gastroenterol. 2013 48:729-735.
23) Ohkawa S, Sakamoto Y, Ueno M. A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy. Gan To Kagaku Ryoho. 2013 Jun;40(6):785-8.
24) Y.Yamada, N.Boku, T.Nishina, K.Yamaguchi, T.Denda, A.Tsuji, Y.Hamamoto, K.Konishi, Y.Tsuji, K.Amagai, S.Ohkawa, Y.Fujita, H.Nishisaki, H.Kawai, A.Takashima, J.Mizusawa, K.Nakamura & A.Ohtsu. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Onology Group Trial JCOG9912. Annals of Oncology. 2013 00:1-6.
25) Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol. 2013 May;71(5):1141-6.doi: 10.1007/s00280-013-2106-0. Epub 2013 Mar 24.
26) Yoshii T, Miyagi Y, Nakamura Y, Kobayashi O, Kameda Y, Ohkawa S. Pilot research for the correlation between the expression pattern of E-cadherin-β-catenin complex and lymph node metastasis in early gastric cancer. Tumori. 2013 Mar-Apr;99(2):234-8. doi: 10.1700/1283.14198.
27) Kameda R, Ando T, Kobayashi S, Ueno M, Ohkawa S. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer. Jpn J Clin Oncol. 2013 Jun;43(6):636-40. doi: 10.1093/jjco/hyt059. Epub 2013 Apr 25.
28) Yoshii T, Ohkawa S, Tamai S, Kameda Y. Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. Dis Esophagus. 2013 Jul;26(5):496-502. doi: 10.1111/j.1442-2050.2012.01370.x. Epub 2012 Jun 7.
29) Masafumi Ikeda, Shinichi Ohkawa, Takuji Okusaka, Shuichi Matsunaga, Satoshi Kobayashi, Chigusa Morizane, Ikue Suzuki, Shunsuke Yamamoto, and Junji Furuse. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Science.2014 105(4):445-462.
30) Satoshi Kobayashi, Makoto Ueno, Shinichi Ohkawa, Kuniyasu Irie, Yoshihiro Goda, Manabu Morimoto. Renal toxicity associated with weekly cisplatin and gemciatbine combination therapy for treatment of advanced biliary tract cancer. Oncology. 2014 87 : 30-39.
31) Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Tatsuya Ioka, Junji Furuse, Shinichi Ohkawa, Hiroyuki Isayama and Narikazu Boku. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Science. 2014 Oct;105(10):1321-6. doi: 10. 1111/cas. 12501.
32) Toru Aoyama, Yusuke Katayama, Masaaki Murakawa, Masahiro Asari, Amane Kanazawa, Akio Higuchi, Manabu Shiozawa, Satoshi Kobayashi, Manabu Morimoto, Shinichi Ohkawa, Makoto Akaike, Naoto Yamamoto, Takaki Yoshikawa, Yasushi Rino, Munetaka Masuda, Soichiro Morinaga. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer. Canser chemother Pharmacol. 2014 DOI 10.1007/s00280-014-2601-y.
33) Masato Matsuyama, H.Ishii, J.Furuse, S.Ohkawa, H.Maguchi, N.Mizuno, T.Yamaguchi, T.Ioka, T.Ajiki, M.Ikeda, K.Hakamada, M.Yamamoto, H.Yamaue, K.Eguchi, W.Ichikawa, M.Miyazaki, Y.Ohashi, Y.Sasaki. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. Invest New Drugs.2014 DOI 10.1007/s10637-014-0197-z.
34) Kuruma S, Egawa N, Kurata M, Honda G, Kamisawa T, Ueda J, Ishii H, Ueno M, Nakao H, Mori M, Matsuo K, Hosono S, Ohkawa S, Wakai K, Nakamura K, Tamakoshi A, Nojima M, Takahashi M, Shimada K, Nishiyama T, Kikuchi S, Lin Y. Case-control study of diabetes-related genetic variants and pancreatic cancer risk in Japan. World J Gastroenterol. Dec 14;20(46):17456-62. doi: 10.3748/wjg.v20.i46.17456.
35) Yamada I, Matsuyama M, Ozaka M, Inoue D, Muramatsu Y, Ishii H, Junko U, Ueno M, Egawa N, Nakao H, Mori M, Matsuo K, Nishiyama T, Ohkawa S, Hosono S, Wakai K, Nakamura K, Tamakoshi A, Kuruma S, Nojima M, Takahashi M, Shimada K, Yagyu K, Kikuchi S, Lin Y. Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan. Asian Pac J Cancer. 2014 Prev.;15(1):391-5.
36) Tatsuya Ioka, Takuji Okusaka, Shinichi Ohkawa, Narikazu Boku, Akira Sawaki, Yosuke Fujii, Yoichi Kamei, Satori Takahashi, Katsushi Namazu, Yoshiko Umeyama, Paul Bycott, and Junji Furuse. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analysis by region, including Japan, from the global randmized Phase III trial. Jpn J Clin Oncol.2015 1-10, doi: 10.1093/jjco/hyv011.
37) C.S.fuchs, S, Azevedo, T.Okusaka, J-L. Van Laethem, L.R. Lipton, H. Riess, C. Szczylik, M.J. Moore, M.Peeters, G.Bodoky, M.Ikeda, B.Melichar, R. Nemecek, S.Ohkawa, A.Swieboda-Sadlej, S.A. Tjulandin, E. Van Cutsem, R.Loberg, V. Haddad. J.L. Gansert, B.A.Bach, A,Carrato. A Phase 3 Randomized, Double-Blind, Placebo-Contrlled Trial of Ganitumuab or Placebo in Combination With Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas: the GAMMA Trial. Annals of Oncology. 2015 Jan 21. pii: mdv027. [Epub ahead of print].
38) Irie K, Morimoto M, Numata K, Kondo M, Moriya S, Shimoyama Y, Nozaki A, Goda Y, Kobayashi S, Ueno M, Ohkawa S, Tanaka K, Maeda S. Enhancement of radiofrequency ablation of the liver combined with transarterial embolization using various embolic agents. Abdom Imaging. 2014 Dec 21. [Epub ahead of print]
39) Kondo M, Morimoto M, Ishii T, Nozaki A, Fukuda H, Numata K, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Shibuya A, Okuse C, Suzuki M, Sakamaki K, Morita S, Maeda S, Tanaka K. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients not responsive to transarterial chemoembolization: a propensity score-based weighting. J Dig Dis. 2014 Dec 15. doi: 10.1111/1751-2980.12221. [Epub ahead of print].
40) Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K, Suzuki M, Morita S, Taguri M, Tanaka K. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. Hepatol Res. 2014 May 6. doi: 10.1111/hepr.12354. [Epub ahead of print]
41) Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y.  Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015 Jul;106(7):883-90. doi: 10.1111/cas.12674. Epub 2015 May 14.
42) S. Ohkawa , T. Okusaka , H. Isayama , A. Fukutomi , K. Yamaguchi , M. Ikeda, A. Funakoshi , M. Nagase , Y. Hamamoto , S. Nakamori , Y. Tsuchiya , H. Baba , H. Ishii , Y. Omuro , M. Sho , S. Matsumoto , N. Yamada , H. Yanagimoto , M. Unno , Y. Ichikawa , S. Takahashi , G. Watanabe , G. Wakabayashi , N. Egawa , M. Tsuda , R. Hosotani , C. Hamada , I. Hyodo. Randomized Phase II Trial of S-1 plus Oxaliplatin versus S-1 in Patients With Gemcitabine-Refractory Pancreatic Cancer. Br J Cancer 2015 Apr 28;112(9):1428-34. doi: 10.1038/bjc.2015.103. Epub 2015 Apr 16.
43) Kobayashi S, Ueno M, Irie K, Goda Y, Aoyama T, Morinaga S, Ohkawa S, Morimoto M. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology. 2015 Jul 29. pii: S1424-3903(15)00622-5. doi: 10.1016/j.pan.2015.07.003. [Epub ahead of print]
44) Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes. 2015 Oct 26;8:609. doi: 10.1186/s13104-015-1565-2.
45) Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H, Boku N. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Cancer Sci. 2015 Aug;106(8):1101-2. doi: 10.1111/cas.12709.
46) Ueno M, Ohkawa S, Morimoto M, Ishii H, Matsuyama M, Kuruma S, Egawa N, Nakao H, Mori M, Matsuo K, Hosono S, Nojima M, Wakai K, Nakamura K, Tamakoshi A, Takahashi M, Shimada K, Nishiyama T, Kikuchi S, Lin Y. Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese. Sci Rep. 2015 Nov 23;5:17018. doi: 10.1038/srep17018.
47) Nitta H, Baba H, Sugimori K, Furuse J, Ohkawa S, Yamamoto K, Minami H, Shimokawa M, Wakabayashi G, Aiba K; CINV Study Group of Japan Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by the CINV Study Group of Japan. Anticancer Res. 2016 Apr;36(4):1929-35..
48) Kobayashi S, Ueno M, Hara H, Irie K, Goda Y, Moriya S, Tezuka S, Tanaka M, Okusaka T, Ohkawa S, Morimoto M. Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer. Oncology. 2016 Jun 16. [Epub ahead of print]
49) Kobayashi S, Ueno M, Kameda R, Moriya S, Irie K, Goda Y, Tezuka S, Yanagida N, Ohkawa S, Aoyama T, Morinaga S, Morimoto M Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction Pancreatology 2016 Jul 11. pii: S1424-3903(16)31146-2. doi: 10.1016/j.pan.2016.07.007. [Epub ahead of print]
50) Nakao H, Wakai K, Ishii N, Kobayashi Y, Ito K, Yoneda M, Mori M, Nojima M, Kimura Y, Endo T, Matsuyama M, Ishii H, Ueno M, Kuruma S, Egawa N, Matsuo K, Hosono S, Ohkawa S, Nakamura K, Tamakoshi A, Takahashi M, Shimada K, Nishiyama T, Kikuchi S, Lin Y. Associations between polymorphisms in folate-metabolizing genes and pancreatic cancer risk in Japanese subjects. BMC Gastroenterol 2016 Jul 29;16(1):83. doi: 10.1186/s12876-016-0503-7.
51) Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 2016 Aug 22. [Epub ahead of print]
52) Morimoto M, Kobayashi S, Moriya S, Ueno M, Tezuka S, Irie K, Goda Y, Ohkawa S. Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization. Abdom Radiol (NY). 2016 Sep 13. [Epub ahead of print]

続きを見る

大川 伸一先生 の所属する医療機関

神奈川県立がんセンター

TEL: 045-520-2222

神奈川県立がんセンター

神奈川県横浜市旭区中尾2丁目3-2

相模鉄道本線「二俣川駅」 北口 シャトルバス運行あり 路線バスも可能(相鉄バス 運転試験場(がんセンター)循環 ライトセンター前下車、所要時間約5分) 徒歩15分

- - -

受付時間: 8:30〜11:30 原則、紹介予約制 科により異なる 臨時休診あり

診療科目: 内科 血液内科 精神科 脳神経外科 呼吸器外科 消化器外科 整形外科 形成外科 皮膚科 泌尿器科 婦人科 眼科 耳鼻咽喉科 リハビリテーション科 放射線科 歯科口腔外科 麻酔科 乳腺外科

院長インタビュー

大川 伸一 先生 の記事